Incyte Corp. (INCY) News
Filter INCY News Items
INCY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INCY News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest INCY News From Around the Web
Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.
INCY vs. VRTX: Which Stock Is the Better Value Option?INCY vs. VRTX: Which Stock Is the Better Value Option? |
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WILMINGTON, Del., January 08, 2025--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Exploring Three High Growth Tech Stocks in the United StatesThe United States market has shown robust performance, climbing by 2.8% over the past week and rising 25% over the past year, with earnings forecasted to grow annually by 15%. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions. |
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?EXEL vs. INCY: Which Stock Is the Better Value Option? |
Incyte price target raised to $70 from $68 at Wells FargoWells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRa |
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host DiseaseThe FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise. |
Incyte to Present at Upcoming Investor ConferenceWILMINGTON, Del., December 17, 2024--Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). |
ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphomaThe inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon. |
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & MoreIt was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight. |
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular LymphomaWILMINGTON, Del., December 10, 2024--Late-Breaking Tafasitamab (Monjuvi®) Data Demonstrate Significantly Improved Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma |